Vincent C. Tam

Tremelimumab plus Durvalumab in Unresectable Hepatocellular Carcinoma

Ghassan K. Abou‐Alfa, George Lau, Masatoshi Kudo et al. · NEJM Evidence · 2022 · 1.3K citations · Full text

Unintended Medication Discrepancies at the Time of Hospital Admission

Patricia Cornish, Simon R. Knowles, Romina Marchesano et al. · Archives of Internal Medicine · 2005 · 946 citations

Pembrolizumab in combination with gemcitabine and cisplatin compared with gemcitabine and cisplatin alone for patients with advanced biliary tract cancer (KEYNOTE-966): a randomised, double-blind, placebo-controlled, phase 3 trial

Robin Kate Kelley, Makoto Ueno, Changhoon Yoo et al. · The Lancet · 2023 · 891 citations · Full text

Urology, Surgical Oncology, Gastrointestinal Oncology +5

Oligomerization of μ- and δ-Opioid Receptors

Susan R. George, Theresa Fan, Zhidong Xie et al. · Journal of Biological Chemistry · 2000 · 551 citations · Full text

Phase 3 randomized, open-label, multicenter study of tremelimumab (T) and durvalumab (D) as first-line therapy in patients (pts) with unresectable hepatocellular carcinoma (uHCC): HIMALAYA.

Ghassan K. Abou‐Alfa, Stephen L. Chan, Masatoshi Kudo et al. · Journal of Clinical Oncology · 2022 · 390 citations

First-line Therapy, Psychotropic Medication, Pathology +25